$DPLO (Diplomat Pharmacy, Inc.)

$DPLO {{ '2016-04-19T20:22:23+0000' | timeago}} • Announcement

$DPLO said it is now filling prescriptions for VENCLEXTA (venetoclax). The drug was recently approved by the U.S. Food and Drug Administration for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion.

$DPLO {{ '2018-01-05T14:38:12+0000' | timeago}} • Announcement

$DPLO, a provider of specialty pharmacy services, has appointed Jeff Park as Interim CEO. Jeff, a member of Diplomat's board, will succeed Phil Hagerman who has retired. Ben Wolin, independent lead director, has been named Chairman of the board of directors. Hagerman will continue to serve as a director and assume the role of Chairman Emeritus.

$DPLO {{ '2017-12-21T16:45:43+0000' | timeago}} • Announcement

$DPLO completed acquisition of Leehar Distributors LLC, doing business as LDI Integrated Pharmacy Services, from Nautic Partners, Oak HC/FT Partners, and LDI management. $DPLO also entered into new $800MM senior secured credit facilities.

$DPLO {{ '2017-11-16T12:54:56+0000' | timeago}} • Announcement

$DPLO has agreed to acquire Leehar Distributors, LLC, doing business as LDI Integrated Pharmacy Services (LDI), from investment firms Nautic Partners, LLC and Oak HC/FT Partners LLC, and management. The transaction is expected to close in 30-60 days. Diplomat will pay LDI $515MM cash and about $80MM in common stock.

$DPLO {{ '2017-11-07T13:56:51+0000' | timeago}} • Announcement

$DPLO agreed to buy Pharmaceutical Technologies, Inc., doing business as National Pharmaceutical Services (NPS). The transaction is expected to close in 30 days. $DPLO will pay NPS $31MM cash and $16MM in $DPLO common stock. NPS is expected to generate about $32MM in net revenue and $5MM in adjusted EBITDA in 2017.

$DPLO {{ '2017-10-02T20:54:00+0000' | timeago}} • Announcement

$DPLO has acquired 8th Day Software and Consulting, LLC. 8th Day Software, based in Tennessee, will operate under $DPLO’s subsidiary Envoy Health Management LLC. Dave Loschinskey, founder of 8th Day, has been named $DPLO’s Chief Information Officer.

$DPLO {{ '2017-09-11T22:17:47+0000' | timeago}} • Announcement

$DPLO has completed its acquisition of Focus Rx Pharmacy Services Inc., a specialty and infusion pharmacy with two locations in New York state. This acquisition bolsters $DPLO’s offering of solutions to meet growing demand for infusion therapies. Focus Rx is expected to generate about $47MM in revenue and $3MM in adjusted EBITDA for 2017.

$DPLO {{ '2017-08-07T20:46:05+0000' | timeago}} • Announcement

Pharma company $DPLO appointed Joel Saban as president, effective August 7. He will be succeeding Paul Urick who has decided to step down. Earleir, Saban served Catamaran Corp. as EVP of pharmacy operations from June 2010 to January 2016. From 1997 to 2010, he served CVS/Caremark Corporation as SVP of industry relations.

$DPLO {{ '2017-08-03T17:58:40+0000' | timeago}} • Webcast

$DPLO said it has been selected by Cycle Pharmaceuticals as the exclusive partner to dispense NITYR tablets, which was recently approved by the FDA. The drug is indicated to treat hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

$DPLO {{ '2017-06-09T09:30:03+0000' | timeago}} • Announcement

Shareholders of $DPLO have elected Jeff Park to its board of directors at the annual meeting. Park, who will be serving a three-year term as a Class-III director, has served as COO of UnitedHealth Group’s OptumRx. Earlier, he was a member of the board of directors of Catamaran Corporation.

$DPLO {{ '2017-05-08T22:10:44+0000' | timeago}} • Webcast

In terms of limited distribution drugs, $DPLO said it is adding number of individual drugs across the country to areas where it has not been filling the other prescriptions. The company added that it is seeing a significant uptick in small and independent PBMs (Pharmacy Benefit Management).

$DPLO {{ '2017-05-08T21:52:34+0000' | timeago}} • Webcast

$DPLO said the brand inflation rate for 1Q17 was in the high mid-single digit. The company expects the brand inflation rate to be in low mid-single digit going through the year and end up in 5% range for FY17.

$DPLO {{ '2017-05-08T20:47:17+0000' | timeago}} • Announcement

$DPLO reported that it has completed the acquisition of Chantilly, Virgin-based health care service center company WRB Communications. WRB will join Envoy Health Management, a subsidiary of $DPLO. Under the agreement terms, Diplomat is paying WRB $24.5MM in cash and $4.5MM in Diplomat common stock.

$DPLO {{ '2017-05-08T20:41:47+0000' | timeago}} • Announcement

For full-year 2017, $DPLO expects revenue of $4.3-4.7Bil. Net income is expected to be $6.5-15.5MM and adjusted EBITDA is expected to be $95-103MM. $DPLO expects diluted EPS of $0.09-0.23 and adjusted EPS of $0.54-0.70.

$DPLO {{ '2017-05-08T20:38:30+0000' | timeago}} • Announcement

$DPLO reported a decrease in 1Q17 earnings. Net income was $4.4MM or $0.06 per share compared to $15.4MM or $0.23 per share in 1Q16. Revenue was $1.07Bil, up 8% compared to 1Q16, driven by approx. $116MM of revenue from acquisitions, approx. $74MM from the impact of manufacturer price increases, and about $48MM from drugs that were new in 2016.

$DPLO {{ '2017-04-12T22:13:28+0000' | timeago}} • Announcement

$DPLO has been selected to provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health's clients and support its in-house mail-order pharmacy, PharmaCorr. The three-year agreement, effective March 17, 2017, supports specialty pharmacy services for 321,000 patients across 25 states.

$DPLO {{ '2017-04-11T13:09:45+0000' | timeago}} • Announcement

Independent specialty pharmacy $DPLO appointed Atul Kavthekar as CFO and Treasurer, effective May 1, 2017. Kavthekar will lead $DPLO's financial operations and investor relations efforts. Kavthekar will report directly to Phil Hagerman, CEO and Chairman of the company.

$DPLO {{ '2017-04-06T20:51:37+0000' | timeago}} • Announcement

$DPLO appointed Former United States Surgeon General Regina Benjamin to its BoD, effective immediately. Benjamin will stand for election at its 2017 annual meeting. She will fill the vacancy created by the resignation of her predecessor on Dec. 31, 2016. With her appointment, the board will consist of 7 directors, 5 of whom are independent.

$DPLO {{ '2017-02-28T21:52:01+0000' | timeago}} • Announcement

$DPLO, which completed the acquisition of Affinity Biotech in Feb. 2017, expects revenue to be $4.3-4.7Bil for 2017. Diluted EPS is expected to be $0.09-0.23 and adjusted EPS is expected to be $0.54-0.70. CEO Phil Hagerman said, "For 2017, we are focused on growing our core oncology business and higher margin infusion and service offerings."

$DPLO {{ '2017-02-28T21:46:03+0000' | timeago}} • Announcement

$DPLO swung to a loss in 4Q16 from a profit in the prior year period, hurt by an impairment charge and higher expenses. Net loss was $1.28MM or 2 cents per share compared to net income of $3.3MM or 5 cents per share in the prior year quarter. Adjusted EPS was $0.08 versus $0.21 a year ago.

$DPLO {{ '2017-02-15T14:49:09+0000' | timeago}} • Announcement

$DPLO announced the appointment of Ben Wolin as independent Lead Director, effective immediately. Mr. Wolin, a member of the Nominating and Corporate Governance Committee and the Audit Committee, was appointed to the newly created position by the company's independent directors.

Recent Transcripts

INFO (IHS Markit Ltd.)
Tuesday, January 16 2018 - 1:00pm
WBA (Walgreens Boots Alliance, Inc.)
Thursday, January 4 2018 - 1:30pm
AOBC (American Outdoor Brands Corporation)
Thursday, December 7 2017 - 10:00pm
HOME (At Home Group Inc.)
Wednesday, November 29 2017 - 9:30pm
VVV (Valvoline Inc.)
Thursday, November 9 2017 - 2:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
PINC (Premier, Inc.)
Monday, November 6 2017 - 10:00pm
DPLO (Diplomat Pharmacy, Inc.)
Monday, November 6 2017 - 10:00pm
CVS (CVS Health Corporation)
Monday, November 6 2017 - 1:30pm
BHF (Brighthouse Financial, Inc.)
Thursday, November 2 2017 - 4:00pm
DWDP (DowDuPont Inc.)
Thursday, November 2 2017 - 12:00pm
MGLN (Magellan Health, Inc.)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
BIVV (Bioverativ Inc.)
Friday, October 27 2017 - 12:00pm
ITGR (Integer Holdings Corporation)
Thursday, October 26 2017 - 9:00pm
WBA (Walgreens Boots Alliance, Inc.)
Wednesday, October 25 2017 - 12:30pm
ESRX (Express Scripts Holding Company)
Wednesday, October 25 2017 - 12:30pm
INFO (IHS Markit Ltd.)
Tuesday, September 26 2017 - 12:00pm
AOBC (American Outdoor Brands Corporation)
Thursday, September 7 2017 - 9:00pm
HOME (At Home Group Inc.)
Tuesday, September 5 2017 - 8:30pm

AlphaGraphics you may like